Lates News

According to the AI Quick News, Guojin Securities released a research report on November 3 giving Weigao Blood Purification (603014.SH) a "buy" rating. The main reasons for the rating include: 1) continuous enhancement of cost control ability and sufficient cash reserves; 2) continuous expansion of strategic layout, expected to strengthen long-term development. (Daily Economic News)